Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile.

Simon E WardMark H HarriesLaura AldegheriAndrea M BradfordElisa BalliniLee DawsonLaurent LacroixJoanne PardoeKathryn StarrAnnette WeilKerry WatersJohn R AtackMarie Woolley

Published in: Journal of psychopharmacology (Oxford, England) (2019)

We conclude that MDI-222 is an AMPAR PAM which enhances cognitive performance in rats and has a significantly improved safety profile in preclinical species.

Keyphrases

cell therapy
mesenchymal stem cells
bone marrow